# Purdue Pharma The privately-held, [[Sackler Family]]-controlled pharmaceutical company that developed, manufactured, and marketed [[OxyContin]] — the brand-name controlled-release oxycodone product whose 1996 launch and subsequent decade-plus of aggressive promotion sit at the center of the American opioid crisis. From 1996 to 2018, Purdue generated estimated total OxyContin revenue of **$35 billion+**. From 2008 to 2019, the Sackler family transferred at least **$11 billion** out of the company. In 2019 Purdue filed for Chapter 11 bankruptcy under the weight of approximately 2,600 lawsuits. After a five-and-a-half year bankruptcy process, a 2024 Supreme Court ruling, and a renegotiated settlement, Purdue was confirmed for reorganization in November 2025 as a public-benefit company called **Knoa Pharma** — with all future profits directed to opioid abatement. The company's distinguishing feature was not its product (oxycodone is a century-old molecule; controlled-release formulations existed before MS Contin); it was its **marketing**, which deployed at industrial scale a set of techniques the family's senior generation had pioneered in the Valium era. The company's distinguishing legal feature is that, despite two federal guilty pleas (2007, 2020) and a settlement structure approaching $10 billion across its lifecycle, **not one Purdue executive or Sackler family member has ever served prison time** for the marketing of OxyContin. → For the family that owned it, see [[Sackler Family]]. For the chronological story, see [[Opioid Crisis Timeline]]. --- ## Background - Founded **1892** in New York City as the Purdue Frederick Company by physicians John Purdue Gray and George Frederick Bingham. - For its first 60 years, an unremarkable generic-pharmaceutical maker known for laxatives (Senokot), Betadine antiseptic, and earwax remover. - **1952** — Acquired for **$50,000** by three brothers — Arthur, Mortimer, and Raymond Sackler, all NYU-trained physicians. Arthur supplied the bulk of the purchase capital from his medical-advertising income at the William Douglas McAdams agency. - For roughly thirty years under Sackler ownership, a respectable mid-tier pharma company. The brothers reinvested in pain-management formulations, particularly the controlled-release technology that would eventually underpin [[OxyContin]]. - **1972** — Acquired the controlled-release technology that would become MS Contin (oral morphine sulfate) and later [[OxyContin]] (oral oxycodone). - **1984** — MS Contin launched in the US for cancer pain. Establishes Purdue's reputation as a serious pain-management company and generates the cash flow that funds OxyContin development. - **1987** — Arthur Sackler dies. His one-third stake is bought out by Mortimer and Raymond for $22.35M (ProPublica). From here the Purdue owners are Mortimer's family ("Side A" in the bankruptcy) and Raymond's ("Side B"); see [[Sackler Family]]. - **1991** — The Purdue Frederick Company is renamed **Purdue Pharma L.P.** with the operating entity restructured as a limited partnership owned by Sackler family trusts. Raymond Sackler is president. - **1995-12-12** — FDA approves [[OxyContin]] for marketing, with a label claim ("Delayed absorption ... is believed to reduce the abuse liability of a drug") that has no clinical-trial support. FDA medical examiner Curtis Wright, who handled the approval, leaves the FDA roughly two years later and joins Purdue at triple his federal salary — a textbook [[Revolving Door]] case. ## The OxyContin Years (1996–2007) - **1996 — Launch.** OxyContin enters the US market with the largest pharmaceutical promotion campaign in industry history to that date. First-year sales target ($48M) is hit four months early. [[Richard Sackler]] sends an internal celebratory email predicting "a blizzard of prescriptions." - **1996–2001 — Sales explosion.** Revenue grows from **$48M (1996) to $1.1B (2000)**. By 2001 OxyContin accounts for ~80% of Purdue revenue. The marketing campaign deploys: - A sales force expanding from 318 reps (1996) to ~1,000 (2001), targeting the highest-prescribing physicians - More than 40 all-expenses-paid pain-management symposia at resorts in Florida, Arizona, and California; ~5,000 physicians, pharmacists, and nurses recruited and trained as speaker-bureau members - A free 7-day or 30-day starter-prescription coupon program - Branded swag (mugs, hats, fishing hats, plush toys, a "Get In The Swing With OxyContin" CD) - The evidence-free claim that addiction risk is "less than 1 percent" - Aggressive promotion of the **80mg pill** — far higher than equivalent oral opioid doses used by competitors - **Promotional spend.** Purdue spent approximately **6–12× more** promoting OxyContin in its first six years than it had spent on MS Contin in its first six years, and substantially more than competitors spent on their lead products. The campaign's intensity, not the molecule itself, was the differentiator. - **2000 — First epidemic stories.** Rural Appalachia — eastern Kentucky, southern West Virginia, southwestern Virginia, southeastern Ohio — becomes the first identified epicenter. "Hillbilly heroin" enters circulation. Local prosecutors and the DEA's diversion-control program begin investigations. - **2001 — Label change.** Under FDA pressure, Purdue removes the "believed to reduce the abuse liability" language from the OxyContin label. The field-marketing materials are slower to change. - **2007-05-10 — First federal guilty plea.** In federal court in Abingdon, Virginia, Purdue Frederick Company pleads **guilty to a felony count of misbranding** OxyContin. Three executives plead guilty to misdemeanor misbranding: CEO Michael Friedman ($19M individual fine), General Counsel Howard Udell ($8M), and Chief Medical Officer Paul Goldenheim ($7.5M). Total combined fine: **$634.5 million**. Sentences: probation, 400 hours of community service, no prison time. The Sackler family is not personally charged. - **2007 — Rhodes Pharmaceuticals spun up.** Immediately after the federal plea, the Sacklers organize a US generic-pharma arm called Rhodes Pharmaceuticals to produce generic oxycodone and other opioids — keeping the same family in the US opioid business under a different corporate label. ## Post-Plea Growth and Reformulation (2008–2018) - **2008–2018** — Despite the 2007 plea, Purdue continues to grow OxyContin sales. Internal documents (later released through state-AG investigations and the bankruptcy) show [[Richard Sackler]] and other family members on the board pressuring management to push higher doses, expand the sales force, target high-prescribing physicians, and identify untapped patient populations. [[Richard Sackler]] in 2008: "We have run out of patients to put on opioids. Future growth requires increasing dosage in existing patients." - **2010 — [[McKinsey & Company]] engagement.** McKinsey advises Purdue on how to "turbocharge the sales" of OxyContin — targeting high-prescribing physicians, building rebate structures, and other tactics that subsequent state-AG investigations characterize as actively designed to increase OxyContin sales in regions already experiencing overdose deaths. McKinsey will settle with state AGs for **$573 million** in 2021 and issue a rare public apology. - **2010-04 — Reformulated OxyContin (OP).** Purdue introduces an abuse-deterrent formulation that is harder to crush. Within months, surveys show that street users have substituted heavily to heroin. **Wave 2** of the opioid crisis is dated to this point. Purdue continues marketing OxyContin to physicians for chronic non-cancer pain throughout the 2010s. - **2014 — "Project Tango."** Internal Purdue documents released during the bankruptcy describe a proposed company strategy to expand into the **addiction-treatment market** — the same family that profited from the addiction now profiting from the treatment. The proposal (associated with [[Kathe Sackler]]) is not publicly executed, but the documents become a centerpiece of state-AG arguments. - **2008–2019 — Wealth transfers out.** The Sackler family transfers at least **$11 billion** from Purdue Pharma to family-controlled trusts, offshore vehicles, and the international Mundipharma group. The transfers are documented in audited financial statements. They are timed, in the aggregate, to remove assets from Purdue's reach before the wave of state-AG litigation can compel them into a bankruptcy estate. - **2015–2018 — State AG cases multiply.** Kentucky settles for $24M (2015). Massachusetts Attorney General [[Maura Healey]], Connecticut AG [[William Tong]], and New York AG [[Letitia James]] file the most aggressive complaints — naming individual Sackler family members as personal defendants, not just the corporation. By 2019, ~2,600 plaintiffs across states, counties, cities, tribes, hospital systems, and individuals are pursuing Purdue and the Sacklers. ## Bankruptcy (2019–2025) - **2019-09-15 — Chapter 11 filing.** Purdue Pharma files for Chapter 11 bankruptcy in the Southern District of New York under Judge Robert Drain. The filing pauses litigation against Purdue. The Sacklers — who have not personally filed for bankruptcy — seek a **third-party nondebtor release** that would extinguish civil claims against the family worldwide in exchange for $4.5B (later raised to $6B+) paid into the bankruptcy estate. - **2020-10-21 — Second federal guilty plea.** Purdue agrees to plead guilty (in federal court, not bankruptcy court) to a federal **felony**: defrauding the United States and violating the federal Anti-Kickback Statute by paying physicians through speaker programs to write more OxyContin prescriptions. Total agreed value: **$8.3 billion**. The plea is structured to be paid largely through the bankruptcy process. No individual Sackler is charged. - **2021-09 — Initial plan confirmation.** Judge Drain approves a reorganization plan that includes the contested nondebtor release. The US Trustee (a Justice Department component, headed by William K. Harrington), several states, and Canadian provinces object and appeal. - **2021–2023 — Appeals.** District court (Judge Colleen McMahon) vacates the release in late 2021. Second Circuit reverses in May 2023, reinstating it. The US Trustee petitions the Supreme Court. The Court grants cert in August 2023 and stays the plan. - **2023-12-04 — Oral argument** at the Supreme Court in [[Harrington v. Purdue Pharma]]. - **2024-06-27 — Supreme Court rules 5–4 against Purdue.** [[Justice Gorsuch]]'s majority opinion (joined by Thomas, Alito, Barrett, and Jackson — a striking cross-ideological alignment) holds that the Bankruptcy Code does **not** authorize nonconsensual nondebtor releases. The Sacklers cannot get a release of all opioid claims against them through Purdue's bankruptcy unless individual claimants consent. The settlement collapses. - **2024-07 to 2025-01** — Six months of bankruptcy mediation produce a new framework: Sacklers pay **more** ($6.5B vs. $6B) over 15 years; Sacklers do **not** get immunity from future suits. - **2025-01-24 — Revised settlement.** State AGs announce a **$7.4 billion** agreement: **$6.5B from Sacklers** over 15 years + **$900M from Purdue**. Purdue will be reorganized as a public-benefit company. - **2025-06-16 — All 50 states join.** All state AGs have signed onto the framework. - **2025-11-14 / 11-18 — Bankruptcy plan confirmed.** (Bench ruling Nov 14; confirmation order entered Nov 18.) Judge Sean Lane (Judge Drain having retired) approves the $7.4B settlement. Purdue Pharma's Chapter 11 case is substantively closed at the corporate level. - **2026-05-01 — Plan takes effect.** Purdue emerges from Chapter 11; its operating assets pass to Knoa Pharma and the Sacklers make their first $1.5B payment (Davis Polk; California and Pennsylvania AG announcements). ## The Post-Bankruptcy Entity: Knoa Pharma Under the plan confirmed in November 2025, which took effect on May 1, 2026, Purdue Pharma was reorganized into a **public-benefit company** called **Knoa Pharma**. Its mandate: - All profits, after operating expenses, flow to **opioid abatement** — addiction treatment, naloxone distribution, harm-reduction infrastructure, and related public-health uses. - No Sackler family member retains any ownership, board seat, or operational role. - Knoa will continue to manufacture OxyContin (the drug, though decreasingly prescribed, remains FDA-approved and clinically appropriate for some end-of-life cancer-pain cases) and other pharmaceuticals, and will use Purdue's pipeline for opioid-overdose-reversal and addiction-treatment products. - The corporate structure is roughly analogous to a perpetual charitable-purpose corporation — the company exists to generate cash for opioid abatement, not to maximize shareholder return. Knoa Pharma is, in a sense, the inverse of every American corporation: it was created not to make money for owners but to repay damage caused by the entity it replaces. ## Conflict Architecture ``` SACKLER FAMILY TRUSTS (Side A + Side B) ├── Own Purdue Pharma L.P. (1952–2025) ├── Own Mundipharma (international affiliates) ├── Own Rhodes Pharmaceuticals (generic opioid arm, est. 2007) └── Transfer ~$11B out 2008–2019 ↓ PURDUE PHARMA L.P. (1991–2025) ├── Markets OxyContin 1996 onward ├── 2007 federal guilty plea + $634.5M fine ├── 2019 Chapter 11 filing ├── 2020 federal felony guilty plea (Purdue itself) ├── Harrington v. Purdue Pharma SCOTUS 2024 — release rejected └── Reorganized (effective 2026-05-01) → Knoa Pharma (public-benefit) ↓ KNOA PHARMA (2026–) ├── All profits → opioid abatement ├── No Sackler ownership or governance └── Continues manufacturing, with public-health mandate ``` ## See Also - [[Sackler Family]] — the owning dynasty - [[OxyContin]] — the product - [[Opioid Crisis Timeline]] — the chronological story - [[Harrington v. Purdue Pharma]] — the 2024 Supreme Court ruling - [[McKinsey & Company]] — the consultancy that designed the "turbocharge" sales strategy - [[Mundipharma]] — Sackler-controlled international affiliate group - [[Rhodes Pharmaceuticals]] — Purdue's generic-opioid spinoff - [[Letitia James]] — NY AG, $1.5B individual state settlement - [[War on Drugs Timeline]] — the parallel carceral story